Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Polyus shareholders approve share split

2/3/25 PLZL

Yakovlev reported for 2024 by RAS

2/3/25 IRKT

Board of Directors of Diasoft recommended dividends

2/3/25 DIAS

Positive Technologies will lay off about 500 IT professionals

2/3/25 POSI

Seligdar received a license for geological exploration at the Fedorovskaya area

2/3/25 SELG

Russneft replenished production by 171%

2/3/25 RNFT

Aeroflot reported for 2024 by RAS

2/3/25 AFLT

Cherkizovo reports for 2024 by RAS

2/3/25 GCHE

Severstal will not pay dividends for Q4 2024

2/3/25 CHMF

Severstal reports for 2024 by IFRS

2/3/25 CHMF